Loading
A mutation that stops osimertinib from binding to EGFR; the main on-target way lung cancers escape it.
EGFR C797S is a mutation at the covalent binding site that stops osimertinib from attaching to EGFR, and it is the main on-target route by which lung cancers escape the drug. It arises in a minority of patients progressing on osimertinib, either in cis or in trans with T790M, and it can be detected in circulating tumour DNA by liquid biopsy. No fourth-generation EGFR inhibitor is yet approved, with BLU-945 and others discontinued or still early, so amivantamab-based and antibody-drug conjugate regimens are the practical answer. The first-line pairing of amivantamab and lazertinib is designed partly to pre-empt this escape route. The term belongs to the wider topic of acquired resistance and appears in the resistance-routes map and the drug-tolerant persister pathway.
In plain words · A growth receptor that is mutated in some lung cancers and overproduced in others; the first great success of targeted pills.
Showing the target this term concerns: EGFR.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, EGFR T790M, Resistance routes: how a blocked pathway comes back, Drug resistance (primary and acquired).
Shares Amivantamab + lazertinib (first-line EGFR NSCLC), Resistance routes: how a blocked pathway comes back, Drug resistance (primary and acquired), Receptor tyrosine kinase activation.
Shares EGFR T790M, Resistance routes: how a blocked pathway comes back, Drug resistance (primary and acquired), Receptor tyrosine kinase activation.
Shares EGFR T790M, Drug-tolerant persister cells, Resistance routes: how a blocked pathway comes back, Drug resistance (primary and acquired).
Shares EGFR T790M, Resistance routes: how a blocked pathway comes back, Drug resistance (primary and acquired), Receptor tyrosine kinase activation.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
Shares EGFR T790M, Resistance routes: how a blocked pathway comes back, Drug resistance (primary and acquired), Receptor tyrosine kinase activation.
Shares Amivantamab + lazertinib (first-line EGFR NSCLC), Acquired resistance to every therapy, EGFR-mutated non-small-cell lung cancer, EGFR.